ALSO READDrugmaker Lupin posts strong Q3; warns competition to drag next year Lupin warns of more pricing pressure as fourth-quarter profit halves Lupin posts better-than-expected Q3 profit as US sales rise Drugmaker Lupin's profit halves as U.S. sales slump Lupin receives tentative approval for Pitavastatin Tablets
In United StatesLupin announced the launch of its Bupropion Hydrochloride Extended Release Tablets USP, 150 mg and 300 mg having received an approval from the USFDA earlier. It is the AB rated generic equivalent of Valent Pharmaceuticals North America, LLC's Wellbutrin XL tablets, 150 mg and 300 mg, which is indicated for the treatment of major depressive disorders and prevention of seasonal affective disorders in adults.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)